Pathological and biochemical consequences of acute and chronic neuroinflammation within the basal forebrain cholinergic system of rats.
Inflammatory processes may play a critical role in the degeneration of basal forebrain cholinergic cells that underlies some of the cognitive impairments associated with Alzheimer's disease. In the present study, the proinflammagen lipopolysaccharide, from the cell wall of Gram-negative bacteria, was used to produce inflammation within the basal forebrain of rats. The effects of acute, high-dose injections of lipopolysaccharide (2, 20 or 40 microg) upon basal forebrain chemistry and neuronal integrity were compared with the effects of chronic, low-dose lipopolysaccharide infusions (0.18, 0.25, 1.8 or 5.0 microg/h) for either 14, 37, 74 or 112 days. Acute exposure to lipopolysaccharide decreased cortical choline acetyltransferase activity and the number of immunoreactive choline acetyltransferase-positive cells within a small region of the basal forebrain. Regional levels of five different neuropeptides were unchanged by acute, high-dose lipopolysaccharide injections. Chronic lipopolysaccharide infusions produced (i) a time-dependent, but not dose-dependent, decrease in cortical choline acetyltransferase activity that paralleled a decline in the number of choline acetyltransferase- and p75-immunoreactive cells within the basal forebrain, and (ii) a dense distribution of reactive astrocytes and microglia within the basal forebrain. Chronic neuroinflammation might underlie the genesis of some neuropathological changes associated with normal ageing or Alzheimer's disease.
Division of Neural Systems, Memory & Aging, University of Arizona, Tucson 85724, USA.
L B
LB
Willard
B
B
Hauss-Wegrzyniak
G L
GL
Wenk
D000208:Acute Disease; D000818:Animals; D002540:Cerebral Cortex / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D002795:Choline O-Acetyltransferase / Q000378:metabolism*; D002908:Chronic Disease; D004926:Escherichia coli; D019004:Galanin / Q000378:metabolism; D007249:Inflammation / Q000378:metabolism* / Q000473:pathology*; D008070:Lipopolysaccharides / Q000633:toxicity; D008297:Male; D015287:Neurokinin B / Q000378:metabolism; D009478:Neuropeptide Y / Q000378:metabolism; D009479:Neuropeptides / Q000378:metabolism*; D009496:Neurotensin / Q000378:metabolism; D016548:Prosencephalon / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology*; D051381:Rats; D011916:Rats, Inbred F344; D013004:Somatostatin / Q000378:metabolism; D013997:Time Factors
D008070:Lipopolysaccharides; D009478:Neuropeptide Y; D009479:Neuropeptides; D009496:Neurotensin; D013004:Somatostatin; D015287:Neurokinin B; D019004:Galanin; D002795:Choline O-Acetyltransferase